- Merck & Co Inc's MRK Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS).
- The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.
- Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients.
- The treatment regime included Keytruda + Chemo combo, then continued as a single agent every six weeks for up to 14 cycles.
- At a pre-specified interim analysis review, the regime demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy alone.
- The safety profile of Keytruda was consistent with that observed in previously reported studies; no new safety signals were identified.
- This trial was sponsored by the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
- Price Action: MRK shares are down 0.63% at $102.81 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in